AU2018325283B2 - Therapeutic metal complexes and ligands and methods of making and using same - Google Patents

Therapeutic metal complexes and ligands and methods of making and using same Download PDF

Info

Publication number
AU2018325283B2
AU2018325283B2 AU2018325283A AU2018325283A AU2018325283B2 AU 2018325283 B2 AU2018325283 B2 AU 2018325283B2 AU 2018325283 A AU2018325283 A AU 2018325283A AU 2018325283 A AU2018325283 A AU 2018325283A AU 2018325283 B2 AU2018325283 B2 AU 2018325283B2
Authority
AU
Australia
Prior art keywords
aliphatic
heteroaliphatic
heteroaryl
aryl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018325283A
Other languages
English (en)
Other versions
AU2018325283A1 (en
Inventor
Chris BEAUDRY
Joseph BECKMAN
James Hurst
John Sirois
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon State University
Original Assignee
Oregon State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon State University filed Critical Oregon State University
Publication of AU2018325283A1 publication Critical patent/AU2018325283A1/en
Application granted granted Critical
Publication of AU2018325283B2 publication Critical patent/AU2018325283B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/005—Compounds containing elements of Groups 1 or 11 of the Periodic Table without C-Metal linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/08—Copper compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018325283A 2017-09-01 2018-08-31 Therapeutic metal complexes and ligands and methods of making and using same Active AU2018325283B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762553714P 2017-09-01 2017-09-01
US62/553,714 2017-09-01
PCT/US2018/049163 WO2019046761A1 (en) 2017-09-01 2018-08-31 THERAPEUTIC METAL COMPLEXES AND LIGANDS, METHODS OF MAKING AND USING SAME

Publications (2)

Publication Number Publication Date
AU2018325283A1 AU2018325283A1 (en) 2020-03-12
AU2018325283B2 true AU2018325283B2 (en) 2023-11-16

Family

ID=63684510

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018325283A Active AU2018325283B2 (en) 2017-09-01 2018-08-31 Therapeutic metal complexes and ligands and methods of making and using same

Country Status (8)

Country Link
US (2) US11596651B2 (enExample)
EP (1) EP3676271A1 (enExample)
JP (3) JP7894113B2 (enExample)
CN (1) CN111278835A (enExample)
AU (1) AU2018325283B2 (enExample)
CA (1) CA3074258A1 (enExample)
IL (1) IL272895B2 (enExample)
WO (1) WO2019046761A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7894113B2 (ja) * 2017-09-01 2026-07-23 オレゴン ステイト ユニバーシティー 治療用金属錯体およびリガンドならびにその作成および使用の方法
EP4003361A1 (en) * 2019-07-25 2022-06-01 ALS Therapy Development Institute Cuptsm for the treatment of neurodegenerative disorders
CN116234800A (zh) * 2020-08-26 2023-06-06 Als治疗发展学会 用于治疗神经退行性病症的铜络合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2166676A1 (en) * 1995-01-09 1996-07-10 Yasuhisa Fujibayashi Diagnostic agent for hypoxia or mitochondrial dysfunction comprising radioactive copper complex of dithiosemicarbazone derivative or diamine diol schiff base derivative
WO2008061306A1 (en) * 2006-11-20 2008-05-29 The University Of Melbourne Metal delivery agents and therapeutic uses of the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7403524A (en) 1959-09-15 1974-05-27 Pharmaceutical compsn. - contg. alpha-dithiosemicarbazone active against trichomonas vaginalis
US4107210A (en) 1976-09-07 1978-08-15 The Dow Chemical Company Synthesis of alpha-diketones
GB0617299D0 (en) * 2006-09-01 2006-10-11 Isis Innovation Compounds for imaging and therapy
WO2010066010A1 (en) 2008-12-12 2010-06-17 The University Of Melbourne Process for the preparation of asymmetrical bis(thiosemicarbazones)
ES2778038T3 (es) * 2013-11-11 2020-08-07 Collaborative Medicinal Development Llc Complejos metálicos y métodos de tratamiento
WO2017070752A1 (en) * 2015-10-29 2017-05-04 The University Of Queensland Imaging agents
WO2017214546A1 (en) * 2016-06-10 2017-12-14 University Of Louisville Research Foundation, Inc. Compounds, related compositions, catalysts, electrochemical cells, fuel cells, their preparation and their uses
WO2018204564A1 (en) * 2017-05-04 2018-11-08 University Of Louisville Research Foundation, Inc. Thiosemicarbazone derivatives as anti-cancer agents
JP7894113B2 (ja) * 2017-09-01 2026-07-23 オレゴン ステイト ユニバーシティー 治療用金属錯体およびリガンドならびにその作成および使用の方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2166676A1 (en) * 1995-01-09 1996-07-10 Yasuhisa Fujibayashi Diagnostic agent for hypoxia or mitochondrial dysfunction comprising radioactive copper complex of dithiosemicarbazone derivative or diamine diol schiff base derivative
WO2008061306A1 (en) * 2006-11-20 2008-05-29 The University Of Melbourne Metal delivery agents and therapeutic uses of the same

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ALSOP, L. et al., " Investigations into some aryl substituted bis(thiosemicarbazones) and their copper complexes", Inorganica Chimica Acta, 2005, vol. 358, pages 2770–2780 *
Ballschmiter, K. et al., "SUBSTITUENTENEFFEKTE BEI LIGAND-METALL-ELEKTRONENUEBERGAENGEN VON Cu(II)-CHELATEN DER α-DIKETO-BIS-THIOSEMICARBAZONE", J. inorg, nucl. Chem. 1978, Vol. 40, pages 631-634. *
CAS Registry Number 1207290-67-2; Entry Date 2010-02-24; (SP-4-4)-[2-[2-[2-[[(2-Aminoethyl)amino](thioxo-.kappa.S)methyl]hydrazinylidene-.kappa.N1]-1-methylpropylidene]-N-methylhydrazinecarbothioamide-.kappa.N2,.kappa.S]copper(2+) *
CAS Registry Number 53557-00-9; Entry Date 1984-11-16; Hydrazinecarbodithioic acid, 2-[2-[[[[2-(diethylamino)ethyl]amino]thioxomethyl]hydrazono]-1-methylpropylidene]-, methyl ester, copper complex *
COATS, E. A. et al., "Comparative Analysis of the Cytotoxicity of Substituted [Phenylglyoxal bis(4-methyl-3-thiosemicarbazone)]copper(II) Chelates", Journal of Medicinal Chemistry, 1976, vol. 19, no. 1, pages 131–135 *
COATS, E. A. et al., Journal of Medicinal Chemistry, 1978, vol. 21, no. 8, pages 804–809 *
DEARLING, J. L. J. et al., ‘Redox-active metal complexes for imaging hypoxic tissues: structure–activity relationships in copper(II) bis(thiosemicarbazone) complexes’, Chemical Communications. 1998, vol.22, pages 2531-2532 *
HALL, I. H. et al., "The Cytotoxicity of Symmetrical and Unsymmetrical Bis(thiosemicarbazones) and Their Metal Complexes in Murine and Human Tumor Cells", Arch. Pharm. Pharm. Med. Chem., 2000, vol. 333, pages 217–225 *
JOHN, E. K. et al., "Structure-Activity Relationships for Metal-Labeled Blood Flow Tracers: Comparison of Keto Aldehyde Bis(thiosemicarbazonato)copper(II) Derivatives", Journal of Medicinal Chemistry, 1990, vol. 33, no. 6, pages 1764–1770 *
SOON, C. P. W. et al., THE JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, vol. 286, no. 51, pages 44035–44044 *

Also Published As

Publication number Publication date
EP3676271A1 (en) 2020-07-08
US12403159B2 (en) 2025-09-02
JP2026041735A (ja) 2026-03-10
IL272895B1 (en) 2025-02-01
JP2020532538A (ja) 2020-11-12
CN111278835A (zh) 2020-06-12
CA3074258A1 (en) 2019-03-07
US20230172977A1 (en) 2023-06-08
US20200188430A1 (en) 2020-06-18
AU2018325283A1 (en) 2020-03-12
US11596651B2 (en) 2023-03-07
IL272895B2 (en) 2025-06-01
IL272895A (en) 2020-04-30
JP2024001064A (ja) 2024-01-09
WO2019046761A1 (en) 2019-03-07
JP7894113B2 (ja) 2026-07-23

Similar Documents

Publication Publication Date Title
JP7688000B2 (ja) 非アポトーシス性の制御された細胞死の阻害剤としてのスピロキノキサリン誘導体
US12403159B2 (en) Therapeutic metal complexes and ligands and methods of making and using the same
JP5112595B2 (ja) 抗炎症活性および抗生物質活性を有する５−ａｓａ誘導体およびこれを用いて疾患を治療する方法
PT2511264E (pt) Agentes indutores de apoptose destinados ao tratamento de cancro e de doenças imunes e autoimunes
WO2010033360A1 (en) Methods of treating a botulinum toxin related condition in a subject
US12286420B2 (en) EAAT2 activators and methods of using thereof
JPS6019753B2 (ja) ベンゾイミダゾ−ル誘導体、その製造方法及びそれを含有する寄生蠕虫防除剤
CN105228984B (zh) 硝羟喹啉碱加成盐及其用途
US12036208B2 (en) Methods for treating neurodegenerative disorders
JP6378179B2 (ja) 新規化合物，有機カチオントランスポーター３の検出剤及び活性阻害剤
CA3195457A1 (en) Methods and compositions for targeted protein degradation
JP6940504B2 (ja) 置換５，６−ジヒドロ−６−フェニルベンゾ［ｆ］イソキノリン−２−アミンを調製するための方法
ES2602056T3 (es) Derivado de imidazopiridina de utilidad en el tratamiento de la diabetes
CN110248656B (zh) 一种蓝萼甲素衍生物及其药学上可接受的盐或药物组合物及在制备治疗银屑病药物中的用途
US20250145591A1 (en) Inhibitors of advanced glycation end products
JP7085994B2 (ja) 線維症疾患の治療及び／又は予防用アミノナフトキノン化合物
TWI680973B (zh) 嗜中性白血球發炎抑制劑及其用途
HUP0204476A2 (en) Therapeutically useful new salts of cck inhibitors, process for the preparation thereof and pharmaceutical compositions containing them
CZ2003126A3 (cs) Krystalické terapeutické činidlo

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)